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Abstract: Integrase is an essential HIV-1-speciﬁ  c enzyme that is an active target for 
antiretroviral drug development. Recently, a new class of drugs that speciﬁ  cally inhibits strand 
transfer, one of the three steps of HIV integration into the host DNA, has been developed. 
Two drugs in this class have reached late stages of development for use in HIV-1 infected 
individuals: raltegravir, which has just been approved for use in treatment-experienced patients, 
and elvitegravir, currently in phase III trials. Both are potent with an IC50 in the 30 nM range and 
active in vitro against wild type as well as in strains highly resistant to all other existing classes 
of drugs. Clinical trials in both treatment-naïve and -experienced patients have demonstrated 
raltegravir to be highly effective with an excellent tolerability proﬁ  le and no speciﬁ  c clinical 
or metabolic side effects. Longer follow up is necessary to ensure this early safety proﬁ  le 
is sustained. The rapid rate of viral decay observed with raltegravir challenges the current 
understanding of HIV-1 turnover and may open new strategies for long term treatment and 
management of infected patients.
Keywords: integrase inhibitors, antiretroviral therapy, treatment failure, raltegravir, 
elvitegravir
Background
Current estimates suggest that there are 33.2 million persons living with HIV infection 
and that despite ongoing prevention efforts, 2.5 million new infections occurred in 
2007 as the pandemic continues. The year 2007 was, however, remarkable on many 
fronts: prevalence rates globally appeared to stabilize or decrease slightly; the total 
number of HIV-infected individuals who were receiving antiviral therapy increased 
to approximately 2.6 million persons, the majority now being in resource-limited 
settings; and new antiretroviral drugs continued to be developed including two from 
new classes which received approval for treatment in HIV-infected patients.1,2
There were setbacks in 2007 as well, mostly on the prevention front. The biggest 
disappointment was the failure of the adenovirus vector vaccine trials, the results of 
which hinted that vaccine recipients may have actually done worse that those who 
received placebo.3,4 Similar failures were observed in microbicide prevention trials.5,6 
Additionally, it was conclusively demonstrated that interrupting therapy was actu-
ally harmful, ending that strategy as a viable alternative.7 The focus on antiretroviral 
treatment, therefore, has retaken center stage. Treatment of HIV-infection with 
antiretroviral agents has regained its importance for multiple reasons: the recent inter-
ventional prevention trials have failed, treatment in the developing world has been 
very rapid and successful, and the newer generation of antiretroviral drugs recently 
approved or in development are very potent and offer signiﬁ  cant advantages in toler-
ance and efﬁ  cacy compared to many of the existing drugs.Therapeutics and Clinical Risk Management 2009:5 332
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For the past 12 years, there have been only 2 HIV 
targets where therapy has been successful in blocking viral 
replication, reverse transcriptase and protease. Although 
there is a drug that inhibits fusion, to date this treatment is 
considered difﬁ  cult and is infrequently utilized primarily 
because of the parenteral administration involved. We now 
have additional options with drugs from 2 new classes: 
inhibitors of viral integrase and small molecules capable of 
blocking the CCR5 chemokine receptor which is essential 
for viral entry into the cell.
One of the most exciting areas in HIV treatment and 
research today involves the integrase inhibitors. Integrase 
is an HIV viral enzyme that is essential for viral replica-
tion. Inhibitors of integrase are completely independent 
in their activity compared to all other antiretroviral drug 
classes including reverse transcriptase, protease, matu-
ration and entry inhibitors. Virus resistant to all know 
drug classes therefore, remain completely susceptible to 
inhibitors of integrase. Additionally, integrase inhibitors 
are active in both CCR5-tropic and CXCR4-tropic HIV-1 
viruses.8,9
One of the ﬁ  rst integrase inhibitors to be developed is 
raltegravir (MK-0518). This drug has been shown to have a 
very potent and rapid antiretroviral effect with a 2 log reduc-
tion in plasma HIV RNA in 10 days of monotherapy.10 This 
drug recently received accelerated but conditional approval 
by the United States Food and Drug Administration and the 
European Medicines Evaluations Agency for the treatment 
of patients failing existing therapy. Further development 
for use in treatment-naïve patients is ongoing. The second 
integrase inhibitor to be developed is elvitegravir (GS 9137). 
This review focuses on these 2 new drugs that inhibit HIV-1 
integrase. Mechanism of action, pharmacokinetics, clinical 
use in treatment-experienced patients, clinical use in treat-
ment-naïve patients, tolerability, resistance proﬁ  le, and other 
potential uses are addressed. The chemical structures of these 
2 compounds are illustrated in Figure 1.
Mechanism of action for integrase 
inhibition
Integrase is an HIV-1 enzyme that is essential for viral repli-
cation. Integrase catalyzes at least 3 reactions: 3´ processing, 
formation of the preintegrase complex, and strand transfer 
(Figure 2). Brieﬂ  y, once the viral RNA is retrotranscribed 
into DNA by reverse transcriptase, integrase removes a 3’ 
terminal portion at both ends of the newly formed DNA 
where it remains bound, stabilizing the preintegrase com-
plex. Once 3’ processing occurs, the preintegrase complex 
can form which consists of ring-shaped viral DNA with 
associated virus and host proteins. This complex structure 
is able to translocate across the nuclear membrane and into 
the nucleus. The ﬁ  nal reaction catalyzed by integrase is the 
strand transfer where both 3’ ends of the DNA are inserted 
into the host DNA or chromosome. The newly altered 
host DNA, which now includes the HIV DNA, requires 
repair which is done with cellular DNA repair enzymes. 
If strand transfer in inhibited, the viral ring structures 
remain in the nuclear cytoplasm, the clinical relevance of 
which is unknown.11–12 Inhibitors of integrase that have 
now been developed are strand transfer inhibitors (INSTIs) 
that block the insertion position on the host DNA. Three 
integrase inhibitor classes of compounds have been identi-
ﬁ  ed: diketoacids, hydroxyquinolones, and polyphenols. 
Raltegravir is a member of the diketoacid class and elvite-
gravir belongs to the hydroxyquinolone class.14
In preclinical studies, raltegravir was found to be effective 
in vitro and safe in animal models. In HIV-1 isolates includ-
ing 6 subtypes with both syncytium and non-syncytium 
inducing isolates, raltegravir inhibited replication in 
peripheral blood mononuclear cells (PBMCs) with cellular 
IC95 values ranging from 6 to 50 nM. It also inhibited 
replication in laboratory HIV-2 isolates, with an average 
cell IC95 of 6.3 nM. Raltegravir did not inhibit any human 
DNA polymerases signiﬁ  cantly nor did it inhibit any tested 
enzyme activity, transporter or receptor-ligand assays. The 
toxicologic effects of raltegravir in the dog and rat were not 
signiﬁ  cant, carcinogenicity studies have been negative to 
date, and the reproduction toxicity studies in rats and rabbits 
were unremarkable; hence raltegravir has been classiﬁ  ed as 
a Pregnancy Category C Drug.15–17
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Figure 1 Chemical structure of 2 integrase inhibitors: a) raltegravir – a diketoacid 
and b) elvitegravir – a hydroxyquinolone.
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Pharmacokinetics of integrase 
inhibitors
One of the main differences between the two most advanced 
INSTI drugs in development is their pharmacokinetic 
properties.
Raltegravir
Raltegravir is primarily metabolized by glucuronidation 
and is mainly excreted in faeces (51%) with the remainder 
excreted in urine (32%). In humans, there is only one 
metabolite, M2, which accounts for most of the dose 
recovered in urine. It is neither a substrate for nor an inhibitor 
of cytochrome P450 enzymes; therefore, it is not expected to 
have signiﬁ  cant drug–drug interactions with drugs that affect 
or are inﬂ  uenced by P450 isoenzymes. Raltegravir is 83% 
bound to human proteins in plasma. The half-life of ralte-
gravir is approximately 9 hours. Twelve hours after dosing, 
the concentration in humans exceeded 33 nM (the in vitro 
IC95 for HIV-1 in 50% normal serum) in all treatment groups 
tested, thus conﬁ  rming the twice daily dosing schedule that 
has been approved for use. The recommended dose is 400 mg 
twice daily administered without regard to fasting and the 
drug is supplied in a 400 mg pill formulation.
Age, gender, race, food, hepatic impairment (Child–Pugh 
scores 7–8) and renal dysfunction had no signiﬁ  cant effects 
on raltegravir pharmacokinetics. Raltegravir has not be 
studied in patients with severe hepatic impairment, but no 
signiﬁ  cant impact on drug levels is expected; nor has it been 
studied in patients on dialysis and therefore it should be 
avoided in that clinical situation, but if necessary, therapeutic 
drug monitoring should be considered. Typical peak plasma 
concentrations in uninfected adults are 4.5 μmol/L and 
concentrations after 12 hours are 142 nmol/L.17–20 Raltegravir 
does not readily cross the blood–brain barrier (Gilles 
Peytavin, personal communication).
Because raltegravir is mainly metabolized through the 
liver enzyme uridine diphosphate–glucuronosyl–transferase 
1A1 (UGT1A1), concentrations are increased by 53% 
if co-administered with atazanavir, a drug which affects 
glucuronidation; however this was associated with no 
increase in adverse effects and no dosing adjustments are 
recommended.21,22 Similarly, co-administration with drugs 
that induce UGT1A1, like rifampin, phenytoin and phenobar-
bital, should be done cautiously and avoided if at all possible. 
If rifampin must be co-administered, consideration should be 
given to doubling the dose of raltegravir as recommended in 
the European Union guidelines; however this approach is not 
recommended by regulatory authorities in the United States 
or by the manufacturer.17
One of the pharmacologic advantages of raltegravir is its 
lack of signiﬁ  cant interactions with drugs metabolized by 
cytochrome P450 isoenzymes. Consequently, there are no 
signiﬁ  cant drug interactions noted nor dosing adjustments 
required with midazolam, efavirenz, ritonavir or any of the 
protease inhibitors, including tipranavir.17,23
Integrase Presents Multiple Potential
Targets for Intervention
PIC
LTRs
Integration
Gap Repair (cellular processes)
1) Integrase binds to the viral DNA
2) Integrase catalytically processes
each of the 3’ ends
3) Integrase joins the
viral and cellular DNAs, strand transfer
Figure 2 Integrase: mechanism of action for integrase inhibition.  Modiﬁ  ed from Hazuda DJ. 2006. Inhibitors of human immunodeﬁ  ciency virus type I integration. Curr Opin 
HIV AIDS. 1:212–217.36
Abbreviations: PIC, preintegration complex; LTRs, long terminal repeats.Therapeutics and Clinical Risk Management 2009:5 334
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Elvitegravir
Elvitegravir is a modiﬁ  ed quinolone antibiotic that is also 
a potent INSTI. Elvitegravir undergoes both oxidative 
metabolism by CYP3A4 and glucuronidation. It is a moderate 
inducer of CYP3A4 and signiﬁ  cant drug-drug interactions 
may occur when other CYP3A4 inducers or inhibitors are 
concomitantly administered. In healthy volunteers, the 
plasma half-life was approximately 3 hours when the drug 
was given alone but half-life is signiﬁ  cantly enhanced if an 
inhibitor of CYP3A4, such as ritonavir, is co-administered. 
When ritonavir is co-administered, steady state exposure 
and minimum plasma concentrations increase 20-fold and 
90-fold, respectively and the plasma half-life increases to 
approximately 9 hours, which then potentially allows for once 
daily dosing (Figure 3). Absorption of elvitegravir is increased 
approximately 3-fold when the drug is co-administered with 
food. Because of the superior performance of the highest 
dose tested in the phase II trial, the drug is being developed 
as 150 mg twice daily administration with ritonavir 100 mg 
in treatment-experienced patients.24,25
Clinical use in treatment-experienced 
patients
Just as many of the more recent antiretroviral agents 
have developed, the initial clinical development for these 
integrase inhibitors has focused on the treatment-experienced 
HIV-infected patient population with drug resistance to the 
available classes of antiretroviral agents.
Raltegravir
A total of  878 patients were studied in the treatment-experienced 
trials of raltegravir: one phase IIb clinical study and 2 large 
identical phase III studies performed in HIV-infected patients 
with triple class drug resistance.
The first study was a phase II dose-ranging study in 
179 treatment-experienced patients with plasma HIV RNA 5000 
copies/mL who were receiving stable antiretroviral treatment 
(ART) for at least 3 months with documented resistance to 
at least one drug in each of the 3 classes of ART. They were 
randomized to optimized therapy (OT) or OT plus 200 mg, 
400 mg or 600 mg twice daily raltegravir. Prior to randomization, 
optimized therapy was selected based on antiretroviral history, 
resistance testing, and prior clinical or laboratory toxicities. 
This population was highly treatment-experienced and had 
received ART for approximately 10 years prior to study entry. 
The baseline plasma HIV RNA level was 4.7 log copies/mL 
and median CD4 count was 240 cells/mm3. Patients had a very 
high level of drug resistance: 66% had a genotype sensitivity 
score (GSS) of 0, 98% were not susceptible to any approved PI, 
and 36% were taking the fusion inhibitor, enfuvirtide, in their 
background therapy.
Elvitegravir (GS 9137)
Steady-State Pharmacokinetics
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Figure 3 Pharmacokinetic properties of elvitegravir with and without ritonavir. Modiﬁ  ed with permission from Iwamoto M, Kassahun K, Troyer MD, et al 2008. Lack of 
pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 48(2):209–214.Therapeutics and Clinical Risk Management 2009:5 335
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In all the raltegravir groups, there was an approximate 
2.0 log10 drop in plasma HIV RNA by week 24, compared 
to optimized therapy alone with placebo which decreased by 
only 0.35 log10 copies/mL (p  0.0001). The proportion of 
patients who decreased their HIV RNA to 400 copies/mL 
at week 24 were 69.8%, 71.1% and 71.1% in the 200 mg, 
400 mg and 600 mg raltergravir arms, respectively, compared 
to 12% in the OT group (p  0.0001). The proportion of 
patients with HIV RNA 50 copies/mL at week 24 was 
65.1%, 55.6% and 66.7% in the raltegravir 200 mg, 400 mg 
and 600 mg arms, respectively, compared to 13.3% in the 
placebo arm (p  0.0001). There were no signiﬁ  cant differ-
ence in viral efﬁ  cacy between the 3 dosage groups studied. 
The CD4 counts increase by 51 to 94 cells/mm3 in the 
raltegravir groups compared to a decrease of 16 cells/mm3 in 
the placebo group (p  0.0001). The use of enfuvirtide in the 
OT improved viral outcomes in all groups. There were few 
adverse events that led to treatment discontinuation. Based 
on these ﬁ  ndings, and those from a phase II treatment-naïve 
study, the 400 mg twice daily dose was chosen for use in 
the phase III trials.22
Two double-blind phase III studies with identical pro-
tocols were performed. BENCHMRK 1 was conducted 
at 65 sites in Europe, Asia and South America and 
BENCHMRK 2 was conducted at 53 sites in North and South 
America. Patients enrolled into these trials had plasma HIV 
RNA 1000 copies/mL and were on stable ART for at least 
2 months. They had to have reduced susceptibility to at least 
one drug in each of the existing 3 classes of ART deﬁ  ned 
as nonnucleoside reverse transcriptase inhibitors (NNRTIs), 
nucleoside analog reverse transcriptase inhibitors (NRTIs) 
and protease inhibitors (PIs). Patients were randomized to 
receive raltegravir 400 mg twice daily or matching placebo 
taken without regard to food. Background therapy could 
include investigational drugs that were under review for 
licensure. Here, for the ﬁ  rst time in a treatment-experienced 
trial, the primary endpoint was the proportion of patients with 
“undetectable” HIV RNA at week 16 with a cutoff of 400 
copies/mL. Patients were stratiﬁ  ed by enfuvirtide use and 
whether they had resistance to 1 or 1 PI. After week 16, 
patients with virologic failure were allowed to receive open-
label raltegravir.
Since the BENCHMRK 1 and 2 studies were identical, 
the combined results are reported. Overall, 699 patients 
were enrolled. Patients were highly treatment experi-
enced with 90% having a history of AIDS and a median 
10 years of prior ART with 12 different drugs. The median 
CD4 count was 119 cells/mm3 and 123 cells/mm3 and the 
median plasma HIV RNA was 4.8 log10 copies/mL and 
4.7 log10 copies/mL for the raltegravir-treated and placebo 
patients, respectively. Overall, 96.3% of patients were 
resistant to 1 PI. Two thirds of patients had a GSS of 0 or 1. 
The proportion who used enfuvirtide in their background 
therapy was approximately 38%, 20% initiating it for the 
ﬁ  rst time in this study.
At week 16, the proportion of patients with HIV RNA 
400 copies/mL was 77.5% for the raltegravir-treated 
patients and 41.9% in the placebo arms (p  0.001). 
Suppression to 50 copies/mL at week 16 was 61.8% in 
the raltegravir patients versus 34.7% in the placebo arms 
(p  0.001). The decrease in plasma HIV RNA at week 24 
was 1.8 log10 copies/mL in the raltegravir arms compared to 
the 0.9 log10  copies/mL for the placebo arm (p  0.001). The 
mean increase in CD4 count from baseline was 84 cells/mm3 
in the raltegravir patients and 36% for those receiving placebo 
(p  0.001) (Figure 4). The treatment effect of raltegravir 
was consistent regardless of baseline HIV RNA, CD4 cell 
count, GSS, phenotypic sensitivity score (PSS), inclusion 
of darunavir and/or enfuvirtide, gender, race, geographic 
region and viral subtype. In patients using either darunavir 
or enfuvirtide for the ﬁ  rst time, the proportion with HIV 
RNA 50 copies/mL at week 24 were 68% to 82% in the 
raltegravir arms compared to 48% to 50% in the placebo 
arms.
The results in the combined analysis were sustained 
out to 48 weeks: the proportion of patients with HIV RNA 
400 copies/mL was 72.3% for raltegravir-treated patients 
compared to 37.1% for those on placebo. The proportion of 
patients with HIV RNA 50 copies/mL was 62.1% versus 
32.9% in the raltegravir and placebo groups (p  0.001). The 
CD4 count increased by 109 cells/mm3 versus 45 cells/mm3, 
respectively (p  0.001).26,27
The prognostic factors (odds ratio) predicting 
400 copies/mL at week 24 included baseline HIV RNA 
(0.35), enfuvirtide use in enfuvirtide-naïve patients (5.05), 
active PI in background ART (2.34), and darunavir use (5.78) 
(Table 1). Discontinuation of treatment because of clinical 
adverse events was 1.9% in the raltegravir arms compared to 
2.1% in the control groups. The discontinuation of treatment 
because of laboratory adverse experiences were 0.2% in the 
raltegravir arms compared to 0.0% in the control arms.28
Elvitegravir
The largest study to date of elvitegravir is a 278 subject phase II, 
dose ranging, non-inferiority, partially blinded trial in treat-
ment experienced patients with at least 1 PI mutation. Therapeutics and Clinical Risk Management 2009:5 336
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No NNRTIs were allowed due to lack of knowledge of 
potential drug–drug interactions at the time the study was 
designed. Three different doses of elvitegravir were stud-
ied: 20 mg/day, 50 mg/day and 125 mg/day. All patients 
received a boosted PI that included 100 mg of ritonavir 
in their background regimen. The baseline HIV RNA was 
4.54 log10 copies/mL and the median CD4 counts was 158 
cells/mm3. Patients were highly treatment-experienced and 
had a median of 11 PI mutations. At week 8, the elvitegravir 
20 mg/day arm was discontinued because of a high rate of 
virological failure and patients were allowed to switch to the 
125 mg/day arm. At week 16, 37% of the control arm patients 
switched to elvitegravir. At week 24, the time of the primary 
endpoint, the time-weighted average change from baseline 
in HIV RNA was −1.2, −1.5 and −1.7 log10 copies/mL for 
the control arm, elvitegravir 50 mg/mL and 125 mg/mL, 
respectively. The only signiﬁ  cant difference between the 3 
arms was that the elvitegravir 125 mg/mL arm was superior to 
the control PI arm (p = 0.01). The proportion of patients with 
HIV RNA 50 copies/mL at week 16 was 30%, 38% and 
40% for the control, elvitegravir 50 mg/day and elvitegravir 
125 mg/day, respectively. The mean increase in CD4 counts 
was 28, 52 and 61 cells/mm3 in the 3 groups, respectively.29 
Because these ﬁ  ndings demonstrated superior virologic 
efﬁ  cacy with the highest drug exposure, further development 
in treatment-experienced patients will utilize elvitegravir at 
150 mg twice daily plus ritonavir 100 mg.
Clinical use in treatment-naïve 
patients
Raltegravir
The only clinical study in treatment-naïve patients is a phase II 
trial, Study 004. This study was a multi-center, double-blind, 
randomized dose-ranging study in ART-naïve patients. 
Part I of this trial included 10 days of raltegravir monotherapy 
100 mg, 200 mg, 400 mg, and 600 mg twice daily (N = 35).10 
Following this, Part II of the study combined these doses of 
raltegravir with standard dosages of tenofovir plus lamivudine 
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and compared this to efavirenz plus tenofovir/lamivudine 
(N = 171). In Part II, the baseline mean plasma HIV RNA 
ranged from 4.7 to 4.9 log10 copies/mL and CD4 ranged 
from 225 to 277 cells/mm3. In Part I, the proportion with 
HIV RNA 400 copies/mL at day 10 ranged from 50.0% to 
57.1% compared to placebo at 0%. In Part II, the proportion 
with HIV RNA 400 copies/mL at week 48 was 85.3% to 
100.0% in the various groups with no signiﬁ  cant difference 
between raltegravir-treated and efavirenz-treated patients. At 
week 48, CD4 counts increased by 140 to 216 cells/mm3 in all 
the groups. Raltegravir was well tolerated in all the treatment 
arms. Interestingly, the rate of viral decay during treatment 
was much greater in the raltegravir arms compared to the 
efavirenz arm. The implications of this ﬁ  nding at the present 
time are speculative but under intense investigation.20
Elvitegravir
Elvitegravir has not been extensively studied in antiretro-
viral-naïve patients. There has been a 10 day monotherapy, 
randomized, double-blind, dose-ranging study in treatment-
naïve and experienced patients. Patients were randomized to 
receive elvitegravir 800 mg twice daily, 400 mg twice daily, 
200 mg twice daily or 800 mg once daily or 50 mg boosted 
by ritonavir 100 mg daily. The median baseline CD4 count 
was 442 cell/mm3 and HIV RNA was 4.75 log10 copies/mL. 
The mean reduction in HIV RNA was 1.91 log10 copies/mL 
in the elvitegravir 800 mg twice daily, 400 mg twice daily 
and 50 mg daily plus ritonavir. This study demonstrated that 
the pharmacokinetic boosting by ritonavir may allow for once 
daily administration in certain populations with a reduced dose 
of elvitegravir.24 Because of concerns by regulators that low 
dose ritonavir administration in treatment-naïve patients who 
are not receiving another protease inhibitor may be at risk for 
developing protease mutations, development of elvitegravir 
boosted by ritonavir in this population has been delayed pend-
ing results of safety and further proof-of-concept studies.
Tolerability and safety
Raltegravir
In the large phase III BENCHMRK trials, the most commonly 
reported adverse events were diarrhea, nausea and headache. 
Across all studies, there was an increased incidence of rash 
in the raltegravir arms, 6.7% compared to 3.9% in controls. 
When raltegravir is co-administered with atazanavir the rate 
is higher (9.4%). With darunavir, the rash rate was 13.5% 
for the cumulative period on study compared to 4.0% in the 
control group also receiving darunavir. Rash is typically 
mild to moderate and rarely results in study drug discontinu-
ation. Rash is included as a speciﬁ  c issue in the overall risk 
management plan for raltegravir.
In the pooled analysis across all the studies, there were no 
drug-related clinical adverse events that occurred at frequen-
cies at least 2% greater in the raltegravir groups compared 
to placebo, however when additional safety information was 
included, clinical events that were 2% in the raltegravir 
group included fatigue (7.9% versus 4.6%), herpes zoster 
(4.1% versus 0.7%) nasopharyngitis (6.1% versus 3.9%) and 
rash (5.3% versus 2.5%).
The tolerability proﬁ  le of raltegravir is very similar in 
patients with and without co-infection with hepatitis B and/or C. 
Table 1 Odds ratio associated with virologic success in the BENCHMRK 1 and 2 trials
Prognostic factor Odds ratio for prognostic factor*
Odds ratio 95% CI P-value
Baseline HIV RNA (log10 copies/mL) 0.35 (0.26, 0.47) 0.001
Enfuvirtide use in OBT in 
enfuvirtide-patients (Yes:No)
5.05 (2.72, 9.38) 0.001
Active PI in OBT determined by 
phenotypic resistance test** (Yes:No)
2.34 (1.43, 3.81) 0.001
Darunavir use in OBT in 
Darunavir-naive patients (Yes:No)
5.78 (3.55, 9.42) 0.001
Treatment 9.24 (5.94, 14.37) 0.001)
Reproduced with permission from Steigbigel RT, Cooper DA, Kumar PN, et al 2008. Raltegravir with optimized background therapy for resistant HIV infection. N Engl J Med. 
359:339–354.27 Copyright © 2008. Massachusetts Medical Society.   All rights reserved.
*An odds ratio of (1, −1, 1) indicates (decreased, equal, increased) probability to respond at Week 24. Odds ratio and p-value were calculated using a logistic regression 
model adjusted for baseline HIV RNA level, enfuvirtide use in OBT with no prior exposure; active PI in OBT determined by phenotypic resistance test, investigational ART 
use in OBT (Darunavir or tipranavir use), study, and treatment.
**Phenotypic resistance test are not available for enfuvirtide and Darunavir, both of them are excluded.
Abbreviations: OBT,optimal background therapy; P, protease inhibitor; ART, antiretroviral therapy.Therapeutics and Clinical Risk Management 2009:5 338
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An imbalance in malignancy rates was originally observed 
in the BENCHMRK trials but this imbalance was not main-
tained after 7 months of follow up and no longer considered 
to be of signiﬁ  cance. Cancers were detected in 3.5% of 
raltegravir and 1.7% of placebo recipients. The relative risk 
of cancer in the raltegravir groups as compared to placebo 
was 1.54 (95% CI, 0.50–634).
There appears to be no signiﬁ  cant effect of raltegravir 
on serum lipids. Other laboratory parameters appear not 
be signiﬁ  cantly affected although there are more grade 2 
AST and ALT elevations in raltegravir-treated patients 
compared to placebo. There were very few grade 3 elevations, 
however.26,28
Elvitegravir
Elvitegravir has been well tolerated in the limited number 
of studies completed to date. Very few patients have 
experienced any severe clinically relevant adverse effects. In 
the phase II trial 1% to 3% of patients discontinued treatment 
because of adverse events.24,29
Resistance proﬁ  le
In vitro resistance testing was done by culturing laboratory 
HIV-1 isolate in human H9 cells in increasing raltegravir con-
centrations over a period of months. The ﬁ  rst change observed 
was Q148K. Subsequently, E138A and G140A were isolated. 
The Q148K, E138A/Q148K and E138A/G140A/Q148K 
mutations resulted in average fold-shift values in IC50  of 
46-fold, 90-fold, and 508-fold, respectively.26,30,31
In the BENCHMRK trials, by week 24, 84 raltegravir-
treated patients had met the deﬁ  nition of virologic failure 
and integrase genotype data were available for 60 patients. 
Of these, 42/60 (70%) showed genotypic evidence of 
raltegravir resistance. This high proportion of patients with 
virlogic failure and resistance mutations suggests a rela-
tively low genetic barrier for the development of resistance 
if viral suppression is not optimal. The risk of developing 
treatment-emergent mutations was greater in patients with 
higher baseline HIV RNA levels or GSS or PSS of 0. Viro-
logic failure was generally associated with mutations at either 
amino acid 148 (Q changed to H, K, Or R) or 155 (N changed 
to H) and possibly through one other pathway, Y143R/C. The 
majority 33/42 (79%) of viruses at the time of virological 
failure contained two or more resistance-associated mutations 
in integrase. Additional mutations associated with the 
148 pathway included G140 S/A and E138K; for the 155 
pathway, mutations included E92A, V151I, T97A, G163R 
and L74M; for the 143 pathway, mutations included L74A/I, 
E92/Q, T97A, I203M and S230R. In a small number, there 
were 2 or more secondary mutations without a mutation at 
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Figure 5 Early virologic effect of raltegravir-based treatment compared to standard efavirenz-based treatment in patients initiating antiretroviral therapy. Modiﬁ  ed with 
permission from McColl DJ, Fransen S, Gupta S, et al 2007. Resistance and cross-resistance to ﬁ  rst generation integrase inhibitors: insights from a phase 2 study of elvitegravir 
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position 148 or 155. These included mutations at L74, E92, 
T97, F121, E138, and G140 all of which had a minimal effect 
on susceptibility.26
In 28/39 patients treated with elvitegravir in a phase II 
study, mutations occurred at E92Q, E138K, Q148R/K/H 
or N155H in 11/28 samples In patients who had failed 
treatment. The presence of the mutations at 148 and 155 
positions suggests that elvitegravir and raltegravir are cross 
resistant.29,32,33
Other potential indications
One of the more exciting features of integrase inihibitor 
development is the dramatic difference in early phase viral 
decay in the treatment-naïve patients evaluated in the Ralte-
gravir 004 Study. While the effect at week 24 was basically 
the same as with a conventional efavirenz-based approach, 
the earlier declines in HIV RNA were signiﬁ  cant when 
compared to the standard approach.20,34 The reason for this 
is unknown but may be due to the more complete inhibition 
of integration offered by this category of compounds.
Exploring what can be a further added value to this new 
class of potent drugs is the additional blocking of low level 
viral replication by attacking a different target. The inte-
grase inhibitors, in addition to other new drugs that attack 
different targets such as entry and viral maturation, could 
possibly be used to create even more potent drug regimens 
that we use today. The dream of eradication of HIV from the 
host has resurfaced because of these additional new classes 
of drugs. Although integrase inhibitors do not penetrate 
all compartments, the more rapid viral decay that has been 
observed with their use in treatment-naïve patients suggest 
that these drugs may favorably impact overall viral burden. 
Additionally, in a small group of patients, viral DNA was 
signiﬁ  cantly decreased compared to standard therapy.35 Future 
trials are already in progress looking at intensiﬁ  cation strate-
gies in patients already suppressed by conventional ART. 
Another approach is more intensive initial therapy. Where 
these approaches will lead remains to be seen; however as 
multiple eradication strategies are appearing on the horizon, it 
is likely that the integrase inhibitors, with their good tolerance 
and high potency, are likely to play an important role.
Summary
Integrase inhibitors are already playing an important role 
in the armamentarium of antiretroviral therapy; raltegravir 
has received accelerated marketing approval for use in 
treatment-experienced patients in the United States and 
Europe. Further worldwide approvals are expected shortly. 
Elvitegravir is progressing to phase III in its development. 
The combination of high potency in treatment-naïve and 
experienced patients, good tolerance, favorable pharmaco-
kinetic properties, no signiﬁ  cant food effect, no observed 
fetal and metabolic toxicity proﬁ  le, makes these compounds 
a signiﬁ  cant addition to the ART regimens available today. 
The observation that integrase inhibitors positively affect 
viral dynamics challenges the current understanding of 
HIV-1 turnover and compartmentalization. The implication 
for this phenomena in the context of high potency and good 
tolerability place integrase inhibitors under intense interest 
at the present time.
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